Journals / Güncel Retina Dergisi / 2020 / Cilt: 4 - Sayı: 2

Pachychoroid Spectrum Diseases and Central Serous Chorioretinopathy Treatment With Subthreshold Micropulse Laser and Photodynamic Thrapy

Pakikoroid Spektrum Hastalıkları ve Santral Seröz Koryoretinopati Tedavisinde Eşik Altı Mikropulse Lazer ve Fotodinamik Tedavi

Pages
126–130
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nowadays, Anti-vascular endothelial growth factor (VEGF) therapy, subthreshold micropulse laser, and verteporfin photodynamic therapy are commonly used treatment modalities.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Th common morphological features of pachychoroid spectrum disease are defined by anincrease in choroidal thickness due to dilatedchoroidal vessels in Haller’s layer.A wide range of clinical alterations has been defined within the pachychoroid disease spectrum including, pachychoroid pigment epitheliopathy, central serous chorioretinopathy, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy, focal choroidal excavation, peripapillary pachychoroid syndrome.
📊
Key Findings & Data:In patientsexperiencing vision loss due to central subretinal flid, pigment epithelial detachment, and choroidal neovascularization, treatment should be considered to improve or stabilize visual function.
💡
Conclusion & Impact:Nowadays, Anti-vascular endothelial growth factor (VEGF) therapy, subthreshold micropulse laser, and verteporfin photodynamic therapy are commonly used treatment modalities.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Th common morphological features of pachychoroid spectrum disease are defined by anincrease in choroidal thickness due to dilatedchoroidal vessels in Haller’s layer.A wide range of clinical alterations has been defined within the pachychoroid disease spectrum including, pachychoroid pigment epitheliopathy, central serous chorioretinopathy, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy, focal choroidal excavation, peripapillary pachychoroid syndrome. In patientsexperiencing vision loss due to central subretinal flid, pigment epithelial detachment, and choroidal neovascularization, treatment should be considered to improve or stabilize visual function. Nowadays, Anti-vascular endothelial growth factor (VEGF) therapy, subthreshold micropulse laser, and verteporfin photodynamic therapy are commonly used treatment modalities.

Özet

Pakikoroid spektrum hastalıklarında ortak morfolojik özellik, Haller tabakasındaki dilate koroid damarları nedeniyle koroid kalınlığında artış olarak tanımlanmaktadır. Geniş bir aralıkta klinik değişikliklerin tanımlandığı pakikoroid spektrumu hastalıkları, pakikoroid pigment epitelyopati, santral seröz koryoretinopati, pakikoroid neovaskülopati, polipoidal koroidal vaskülopati, fokal koroidal ekskavasyon ve peripapillar pakikoroid sendromunu kapsamaktadır. Santral subretinal sıvı, pigment epitel dekolmanı ve koroidal neovaskülarizasyon nedeniyle görme kaybı yaşayan hastalarda, görme fonksiyonunu iyileştirmek veya stabilize etmek için tedavi düşünülmelidir. Günümüzde Anti-vasküler endotelyal büyüme faktörü (VEGF) enjeksiyonları, eşik altı mikropulse lazer fotokoagülasyon ve vertoporfirin fotodinamik tedavisi yaygın olarak kullanılan tedavi modaliteleridir

🔖

Cite This Article

AKKAYA, S., KOCABABAŞ, D. Ö. (2020). Pachychoroid Spectrum Diseases and Central Serous Chorioretinopathy Treatment With Subthreshold Micropulse Laser and Photodynamic Thrapy. Güncel Retina Dergisi, Cilt: 4 - Sayı: 2, 126–130. https://ajindex.com/articles/158906

References (15)

  1. Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. 2016
  2. 36(3):499-516. 2. Balaratnasingam C,Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB. Polypoidal Choroidal Vasculopathy: A Distinct Disease or Manifestation of Many? Retina. 2016
  3. 36(1):1-8 3. Lee WK, Baek J, Dansingani KK, Lee JH, Freund KB. Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina.2016
  4. 36(1):73-82. 4. Yannuzzi LA, Freund KB, Goldbaum M, Scassellati-Sforzolini B, Guyer DR, Spaide RF et al. Polypoidal choroidal vasculopathy masquerading as central serouschorioretinopathy. Ophthalmology.2000
  5. 107(4):767–777. 5. Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina. 2012
  6. 32(9):1829– 1837. 6. KumarV, KumarP, RavaniR, GuptaP. Macular telangiectasia type II with pachychoroid spectrumof macular disorders. Eur J Ophthalmol.2019
  7. 29(2):216-222. 7. Stefánsson E. Th Mechanism of Retinal Photocoagulation – How Does the Laser Work? European Ophthalmic Review.2009
  8. 2(1):76-9. 8. Ulbig MR, Arden GB, Hamilton AM. Color contrast sensitivity and pattern electroretinographic findings aftr diode and argon laser photocoagulation in diabetic retinopathy.Am J Ophthalmol. 1994
  9. 117(5):583-588. 9. Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis aftr laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992
  10. 113(6):652- 656. 10. Pearson AR, Tanner V, Keightley SJ, Casswell AG. What effct does laser photocoagulation have on driving visual fields in diabetics? Eye (Lond). 1998
  11. 12(1):64-68. 11. Paulus YM, Palanker D, Blumenkranz MS. Short-pulse Laser Treatment: Redefining Retinal Thrapy. Retinal Physician. 2010
  12. Mainster MA. Wavelength selection in macular photocoagulation. Tissue optics, thermal effcts, and laser systems. Ophthalmology. 1986
  13. 93(7):952- 958. 13. Ricci F, Missiroli F, Regine F, Grossi M, Dorin G. Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2009
  14. 247(5):597-607. 14. Parodi MB, La Spina C, Berchicci L, Petruzzi G, Bandello F. Photosensitizers and Photodynamic Thrapy: Verteporfin. Dev Ophthalmol. 2016
  15. Koytak A, Er